Edition:
United States

Cellectis SA (ALCLS.PA)

ALCLS.PA on Paris Stock Exchange

25.78EUR
11:35am EDT
Change (% chg)

€-0.58 (-2.20%)
Prev Close
€26.36
Open
€26.12
Day's High
€26.26
Day's Low
€25.60
Volume
43,212
Avg. Vol
89,068
52-wk High
€30.00
52-wk Low
€18.20

Select another date:

Wed, Jun 13 2018

BRIEF-Cellectis Publishes Methods to Improve Clinical Use of Chimeric Antigen Receptor T-Cell Therapy

* ANNOUNCED ON TUESDAY NOVEL METHODS TO IMPROVE THE CLINICAL USE OF CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY

BRIEF-Cellectis Announces Approval Of Amendment To Protocol For UCART123 Phase 1 Clinical Trial

* ANNOUNCED ON TUESDAY APPROVAL OF AMENDMENT TO PROTOCOL FOR PHASE 1 CLINICAL TRIAL OF UCART123 PRODUCT CANDIDATE IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS

BRIEF-Cellectis Submits Investigational New Drug Application To FDA For UCART22

* SAID ON WEDNESDAY IT HAS SUBMITTED INVESTIGATIONAL NEW DRUG (IND) APPLICATION TO THE US FDA REQUESTING APPROVAL TO INITIATE A PHASE 1 CLINICAL TRIAL FOR UCART22

BRIEF-Cellectis Partners With Harvard’S Wyss Institute For Research On Human Genome

* SAID ON TUESDAY THAT HARVARD’S WYSS INSTITUTE PARTNERS WITH CELLECTIS TO RECODE HUMAN GENOME

BRIEF-Cellectis Announces Launch Of 175 Million Dollar Underwritten Public Offering Of Its American Depositary Shares

* ANNOUNCED ON WEDNESDAY LAUNCH OF FOLLOW-ON UNDERWRITTEN PUBLIC OFFERING OF $175 MLN OF ITS AMERICAN DEPOSITARY SHARES (ADS)

BRIEF-Cellectis Q4 Operating Loss Widens To 27.8 Million Dollars

* REPORTED ON MONDAY Q4 TOTAL REVENUES OF $6.9 MILLION VS $13.0 MILLION YR AGO

France's Cellectis wins U.S patents for gene editing technology

PARIS The United States has granted French cell therapy group Cellectis two patents to deploy a technology known as CRISPR in T cells, which play a key role in the immune response to cancer, the company said on Tuesday.

France's Cellectis wins U.S patents for gene editing technology

PARIS, Feb 13 The United States has granted French cell therapy group Cellectis two patents to deploy a technology known as CRISPR in T cells, which play a key role in the immune response to cancer, the company said on Tuesday.

Select another date: